Radiation therapy

American Shared Hospital Services Enters Into Agreement to Acquire 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island

Retrieved on: 
Monday, November 20, 2023

SAN FRANCISCO, CA, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ​​via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (“ASHS” or the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced that it has entered into an Investment Purchase Agreement (the “IPA”) to purchase a 60% majority equity interest in the Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, both Rhode Island limited liability companies (collectively, the “Target Companies”), as well as certain payor contracts, from GenesisCare USA, Inc., a Florida corporation (the “Seller”), for a purchase price of $2.85 million. ProspectCharterCARE, LLC d/b/a Roger Williams Medical Center and the Care New England (CNE) Health System each own 20% of the Target Companies.

Key Points: 
  • The Target Companies operate three fully functional turn-key radiation therapy cancer centers in Rhode Island, and all three sites are equipped with state-of-the-art cancer treatment technology using Linear Accelerators (LINACs) and comprehensive treatment planning software.
  • The centers are all located on or adjacent to hospital campuses and include the Southern New England Regional Cancer Centers d/b/a Maddock Radiation Therapy in Warwick, RI, and d/b/a Landmark Radiation Therapy in Woonsocket, RI.
  • The third facility is the Roger Williams Cancer Center d/b/a Roger Williams Radiation Therapy in Providence, RI.
  • These patients would have had to interrupt their life-saving treatment and attempt to seek radiation therapy elsewhere.

The Inner Circle Acknowledges, Anand Kuruvilla as a Top Pinnacle Professional for his contributions to the field of Radiation Oncology

Retrieved on: 
Friday, December 22, 2023

PALATKA, Fla., Dec. 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Anand Kuruvilla is acknowledged as a Top Pinnacle Professional for his contributions to the field of Radiation Oncology.

Key Points: 
  • PALATKA, Fla., Dec. 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Anand Kuruvilla is acknowledged as a Top Pinnacle Professional for his contributions to the field of Radiation Oncology.
  • He earned an American post-graduate degree in radiation oncology from SUNY Downstate Medical Center in New York, where he was also the chief resident during his final year.
  • Board-certified in radiation oncology, Dr. Kuruvilla focuses on and specializes in treating various adult cancers with irradiation.
  • He has been instrumental in establishing and growing the Cancer Center of Putnam, serving as the Director of Radiation Oncology since its opening in 1991.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, November 14, 2023

MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.

Key Points: 
  • The Company is exploring potential strategic alternatives, as it is not feasible to conduct an additional trial with the Company’s current resources.
  • Research and development expenses were $6.1 million in the third quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $5.0 million in the third quarter of 2023, compared to $4.9 million for the same period in 2022.
  • As of September 30, 2023, Galera had cash, cash equivalents and short-term investments of $28.4 million.

Sensus Healthcare Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

BOCA RATON, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • Revenues for the third quarter of 2023 were $3.9 million, compared with $9.0 million for the third quarter of 2022.
  • Cost of sales was $1.9 million for the third quarter of 2023, compared with $3.1 million for the prior-year quarter.
  • Selling and marketing expense was $1.3 million for the third quarter of 2023, compared with $1.8 million for the prior-year quarter.
  • General and administrative expense was $1.5 million for the third quarter of 2023, compared with $1.2 million for the third quarter of 2022.

Fuse Oncology Announces Strategic Collaboration with Radiation Oncology Leader

Retrieved on: 
Thursday, December 14, 2023

BOONE, N.C., Dec. 14, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a leading innovator in cutting-edge radiation oncology solutions, announced today a strategic collaboration with the University of Michigan , a recognized leader in radiation oncology.

Key Points: 
  • BOONE, N.C., Dec. 14, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a leading innovator in cutting-edge radiation oncology solutions, announced today a strategic collaboration with the University of Michigan , a recognized leader in radiation oncology.
  • "Being an integral part of this transformative venture is truly inspiring," said Martha Matuszak, PhD, director of the physics division in U-M's Department of Radiation Oncology.
  • Fuse's collaboration with U-M and Cone Health combines the expertise and resources of two radiation oncology powerhouses—sparking a new wave of innovation and product development.
  • We are experiencing an exciting venture energy in the industry that makes this so rewarding," said Benjamin (BJ) Sintay, Executive Director of Radiation Oncology at Cone Health & Chief Innovation Officer at Fuse Oncology.

Susan G. Komen® Breast Cancer Research Awards Presented To Exceptional Breast Cancer Physician Scientists And Research Advocate

Retrieved on: 
Wednesday, December 6, 2023

SAN ANTONIO, Dec. 6, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, will present awards to four dedicated physician scientists and a pioneering research advocate for their work to drive discoveries and improve breast cancer patient outcomes. They will be recognized tonight at the Susan G. Komen Breast Cancer Research Awards event in San Antonio.

Key Points: 
  • SAN ANTONIO, Dec. 6, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, will present awards to four dedicated physician scientists and a pioneering research advocate for their work to drive discoveries and improve breast cancer patient outcomes.
  • They will be recognized tonight at the Susan G. Komen Breast Cancer Research Awards event in San Antonio.
  • This evening's awardees have made significant contributions in breast cancer research and clinical practice, both of which are critical to fighting this disease.
  • They have advanced our understanding of the mechanisms underlying the genesis of breast cancer (Basic Science) and have pioneered advances in breast cancer care (Clinical Research).

Global Leader Advancing Cancer Treatment, Dr. Christel Smith, Joins Fuse Oncology as Chief Technology Officer

Retrieved on: 
Monday, November 20, 2023

BOONE, N.C., Nov. 20, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a trailblazing leader in radiation oncology software solutions, is pleased to announce the appointment of Dr. Christel Smith as its new Chief Technology Officer. An accomplished physicist and product innovator with a diverse background spanning physics, medicine, and technology, Dr. Smith joins the Fuse team with a wealth of experience and a passion for revolutionizing cancer care.

Key Points: 
  • BOONE, N.C., Nov. 20, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a trailblazing leader in radiation oncology software solutions, is pleased to announce the appointment of Dr. Christel Smith as its new Chief Technology Officer.
  • Dr. Smith's exceptional background in developing software that elevates oncology practices and improves cancer treatment across the globe makes her a valuable addition to the Fuse Oncology team.
  • As the new Chief Technology Officer, Dr. Smith will play a crucial role in advancing the company's mission to transform cancer care through technology.
  • "I am honored to join the Fuse Oncology team, where my passion for physics and my commitment to cancer care innovation converge," said Dr. Smith.

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

Retrieved on: 
Wednesday, November 15, 2023

NEW YORK, Nov. 15, 2023 /PRNewswire-PRWeb/ -- The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

Key Points: 
  • The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
  • The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
  • "Cancer target discovery research has traditionally concentrated on pinpointing genes that facilitate cancer cell growth and survival.
  • It allows them to see how cancer genes affect not only cancer cells but also the immune system within tumors.

Vander-Bend Manufacturing and Subsidiaries Announce Strategic Transformation to Become One Company, with One Vision for the Future as Vantedge Medical

Retrieved on: 
Wednesday, November 8, 2023

For more than 40 years, Vander-Bend has been partnering with customers in complex precision manufacturing and assembly with differentiated engineering, prototyping support, and quality systems.

Key Points: 
  • For more than 40 years, Vander-Bend has been partnering with customers in complex precision manufacturing and assembly with differentiated engineering, prototyping support, and quality systems.
  • The Company primarily serves medical technology markets including Robotic Assisted Surgery and Radiation Oncology, among other high-growth end markets.
  • To offer a more streamlined and impactful customer experience, all five manufacturing companies will now unify under a single, cohesive brand – Vantedge Medical.
  • We couldn't be more enthusiastic about working alongside the team as one company, Vantedge Medical."